Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism (Q28079081)

Jennifer Priziola

2

1 reference

Paul P. Dobesh

3

1 reference

Diane Wirth

4

1 reference

Adam Cuker

5

1 reference

Ann K. Wittkowsky

6

1 reference

language of work or name

1 reference

January 2016

1 reference

Journal of Thrombosis and Thrombolysis

1 January 2016

4 references

22 March 2019

17 June 2019

18 November 2019

12 December 2020

5 references

22 March 2019

17 June 2019

18 November 2019

12 December 2020

41

1 reference

issue

1

1 reference

page(s)

165-86

1 reference

Creative Commons Attribution 4.0 International

copyright license

4 references

22 March 2019

17 June 2019

18 November 2019

on focus list of Wikimedia project

12 December 2020

copyright status

copyrighted

0 references

ScienceSource

0 references

cites work

Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715846

Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715846

Home versus in-patient treatment for deep vein thrombosis

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715846

Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715846

Procedures for the outpatient management of patients with deep venous thrombosis

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715846

Oral rivaroxaban for symptomatic venous thromboembolism

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715846

Frequent off-label use of fondaparinux in patients with suspected acute heparin-induced thrombocytopenia (HIT)--findings from the GerHIT multi-centre registry study

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715846

Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715846

Outpatient treatment of symptomatic pulmonary embolism: a systematic review and meta-analysis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715846

Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715846

Anticoagulant failure in coagulopathic patients: PTT confounding and other pitfalls

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715846

Intentional low-molecular-weight heparin overdose: a case report and review

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715846

Enoxaparin outcomes in patients with moderate renal impairment.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715846

Assessing the impact of a heparin-induced thrombocytopenia protocol on patient management, outcomes and cost

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715846

Update in the diagnosis and management of heparin-induced thrombocytopenia

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715846

Unfractionated heparin for the treatment of venous thromboembolism: best practices and areas of uncertainty

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715846

Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715846

Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715846

Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715846

New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715846

Emergency reversal of pentasaccharide anticoagulants: a systematic review of the literature

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715846

Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonin-release assay: a 30-month, 16-patient case series

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715846

Low-Molecular-Weight Heparin Overdose: Management by Observation

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715846

Recombinant factor VIIa to manage major bleeding from newer parenteral anticoagulants

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715846

Unfractionated heparin dosing for venous thromboembolism in morbidly obese patients: case report and review of the literature

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715846

Dabigatran versus warfarin in the treatment of acute venous thromboembolism

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715846

Using low molecular weight heparin in special patient populations

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715846

Fondaparinux and the management of heparin-induced thrombocytopenia: the journey continues

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715846

Treatment of venous thromboembolism: guidelines translated for the clinician

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715846

Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715846

Pharmacokinetic and clinical data supporting the use of fondaparinux 1.5 mg once daily in the prevention of venous thromboembolism in renally impaired patients

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715846

Delayed-onset HIT caused by low-molecular-weight heparin manifesting during fondaparinux prophylaxis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715846

Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715846

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715846

Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715846

Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715846

Enoxaparin dosage adjustment in patients with severe renal failure: antifactor xa concentrations and safety.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715846

Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715846

Predicting adverse outcome in outpatients with acute deep vein thrombosis. findings from the RIETE Registry

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715846

Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715846

Fondaparinux: a potential new therapy for HIT.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715846

The safety of dosing dalteparin based on actual body weight for the treatment of acute venous thromboembolism in obese patients

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715846

Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715846

Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715846

Unfractionated heparin dosing nomograms: road maps to where?

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715846

Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715846

Management of venous thromboembolism: past, present, and future

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715846

Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715846

Antithrombotic therapy for venous thromboembolic disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715846

Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715846

College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715846

The relation between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715846

Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715846

Peak antifactor xa activity produced by dalteparin treatment in patients with renal impairment compared with controls

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715846

College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: the clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715846

Use of low molecular weight heparin (dalteparin), once daily, for the treatment of deep vein thrombosis. A feasibility and health economic study in an outpatient setting. Swedish Venous Thrombosis Dalteparin Trial Group

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715846

The weight-based heparin dosing nomogram compared with a "standard care" nomogram. A randomized controlled trial

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715846

A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715846

Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715846

Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin). Results of a double-blind randomized study.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715846

Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715846

Relationship between the anticoagulant and antithrombotic effects of heparin in experimental venous thrombosis

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715846

Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism

2 June 2018

1 reference

https://api.crossref.org/works/10.1007/S11239-015-1315-2

Limitations of a standardized weight-based nomogram for heparin dosing in patients with morbid obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11239-015-1315-2

The influence of extreme body weight on clinical outcome of patients with venous thromboembolism: findings from a prospective registry (RIETE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11239-015-1315-2

Interlaboratory variation in heparin monitoring: Lessons from the Quality Management Program of Ontario coagulation surveys

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11239-015-1315-2

Discordant aPTT and anti-Xa values and outcomes in hospitalized patients treated with intravenous unfractionated heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11239-015-1315-2

Achieving target antifactor Xa activity with a heparin protocol based on sex, age, height, and weight

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11239-015-1315-2

A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11239-015-1315-2

Challenges to the effective use of unfractionated heparin in the hospitalized management of acute thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11239-015-1315-2

Weight-based heparin protocol using antifactor Xa monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11239-015-1315-2

Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism. American-Canadian Thrombosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11239-015-1315-2

A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11239-015-1315-2

Oral rivaroxaban for the treatment of symptomatic pulmonary embolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11239-015-1315-2

Oral apixaban for the treatment of acute venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11239-015-1315-2

Dose capping enoxaparin is unjustified and denies patients with acute coronary syndromes a potentially effective treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11239-015-1315-2

Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11239-015-1315-2

Assessment of bleeding events associated with short-duration therapeutic enoxaparin use in the morbidly obese

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11239-015-1315-2

Dosage of enoxaparin among obese and renal impairment patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11239-015-1315-2

Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11239-015-1315-2

How useful is the monitoring of (low molecular weight) heparin therapy by anti-Xa assay? A laboratory perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11239-015-1315-2

Anti-Xa monitoring of enoxaparin for acute coronary syndromes in patients with renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11239-015-1315-2

Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11239-015-1315-2

Protamine reversal of low molecular weight heparin: clinically effective?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11239-015-1315-2

Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11239-015-1315-2

Subcutaneous Fondaparinux versus Intravenous Unfractionated Heparin in the Initial Treatment of Pulmonary Embolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11239-015-1315-2

Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11239-015-1315-2

Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11239-015-1315-2

Assessment of three chromogenic and one clotting assays for the measurement of synthetic pentasaccharide fondaparinux (Arixtra) anti-Xa activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11239-015-1315-2

Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11239-015-1315-2

Reversal of the inhibitory effect of fondaparinux on thrombin generation by rFVIIa, aPCC and PCC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11239-015-1315-2

Use of recombinant factor VIIa (NovoSeven®) in 8 patients with ongoing life-threatening bleeding treated with fondaparinux

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11239-015-1315-2

Safety and efficacy of low-dose fondaparinux (1.5 mg) for the prevention of venous thromboembolism in acutely ill medical patients with renal impairment: the FONDAIR study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11239-015-1315-2

Clarification of once-daily low-molecular-weight heparin dosing in pulmonary embolism

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715846

Two sensitive and rapid chromogenic assays of fondaparinux sodium (Arixtra) in human plasma and other biological matrices

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715846

Absence of interaction of fondaparinux sodium with digoxin in healthy volunteers

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715846

Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low-molecular- weight heparin for the treatment of venous thromboembolism

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715846

Optimal Therapeutic Level of Heparin Therapy in Patients With Venous Thrombosis

27 November 2018

1 reference

https://api.crossref.org/works/10.1007/S11239-015-1315-2

Apparent heparin resistance from elevated factor VIII during pregnancy

21 January 2018

1 reference

12 December 2020

Anti-Xa monitoring: inter-assay variability

1 reference

12 December 2020

Use of the activated partial thromboplastin time for heparin monitoring

1 reference

12 December 2020

The heparin anti-Xa therapeutic range: are we there yet?

1 reference

12 December 2020

Test of the month: The chromogenic antifactor Xa assay

1 reference

12 December 2020

Antithrombotic therapy for venous thromboembolic disease

1 reference

12 December 2020

A Standard Heparin Nomogram for the Management of Heparin Therapy

1 reference

12 December 2020

Pharmacokinetics of a low molecular weight heparin (Fraxiparine) in various stages of chronic renal failure

1 reference

12 December 2020

Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis. A meta-analysis

1 reference

12 December 2020

Antithrombotic therapy for venous thromboembolic disease

1 reference

12 December 2020

Antithrombotic therapy for venous thromboembolic disease

1 reference

12 December 2020

Development and clinical evaluation of two chromogenic substrate methods for monitoring fondaparinux sodium

1 reference

12 December 2020

Effect of fondaparinux on coagulation assays: results of College of American Pathologists proficiency testing

1 reference

12 December 2020

Monitoring unfractionated heparin with the aPTT: time for a fresh look

1 reference

12 December 2020

Heparin-induced thrombocytopenia associated with fondaparinux

1 reference

12 December 2020

Clinical outcome of patients with venous thromboembolism and renal insufficiency. Findings from the RIETE registry

1 reference

12 December 2020

Fifty per cent of patients with pulmonary embolism can be treated as outpatients

1 reference

12 December 2020

A comparison of the original and simplified Pulmonary Embolism Severity Index

1 reference

12 December 2020

Antithrombotic therapy for venous thromboembolic disease

1 reference

12 December 2020

Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis

1 reference

12 December 2020

Antagonism of SR 90107A/Org 31540-induced bleeding by protamine sulfate in rats and mice

1 reference

12 December 2020

10.1007/S11239-015-1315-2

Identifiers

DOI

0 references

1 reference

PubMed publication ID

26780745

1 reference